Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Suman Lamsal

Internal Medicine Bayboro, NC Medical Doctor

NPI 1235179698 CMS profile 147277

606 Main St, Bayboro, NC 28515

Open in the dashboard

General payments

$5,599

314 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Suman Lamsal of Bayboro, NC is reported in the CMS Open Payments database as having received $5,599 across 314 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $552 24
2024 General $879 51
2023 General $881 50
2022 General $922 50
2021 General $1,304 72
2020 General $460 31
2019 General $601 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Suman Lamsal
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Suman Lamsal were reported at $552. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Suman Lamsal Internal Medicine median Middle half National median
2019 $601 $159 $48–$570 $163
2020 $460 $119 $33–$402 $114
2021 $1,304 $135 $37–$521 $132
2022 $922 $141 $42–$496 $149
2023 $881 $149 $45–$519 $160
2024 $879 $154 $47–$537 $164
2025 $552 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $843 31 payments
  2. GlaxoSmithKline, LLC. $781 37 payments
  3. Novo Nordisk Inc $635 43 payments
  4. Lilly USA, LLC $432 24 payments
  5. Janssen Pharmaceuticals, Inc $248 23 payments
  6. AbbVie, Inc. $244 13 payments
  7. Amgen Inc. $242 16 payments
  8. Novartis Pharmaceuticals Corporation $237 15 payments
  9. Amarin Pharma Inc. $217 17 payments
  10. Otsuka America Pharmaceutical, Inc. $216 10 payments
  11. Other $1,504 85 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,555 312 payments
  2. Education $44 2 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $575 27 payments
  2. FARXIGA $552 11 payments
  3. Ozempic $387 28 payments
  4. RYBELSUS $350 26 payments
  5. AIRSUPRA $276 8 payments
  6. XARELTO $248 23 payments
  7. JARDIANCE $217 12 payments
  8. REXULTI $216 10 payments
  9. MOUNJARO $201 11 payments
  10. SHINGRIX $179 8 payments
  11. Other $4,726 279 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 199 drugs

Part D claims

15,506

Median for Internal Medicine: 777

Drug cost

$1,208,029

Median for Internal Medicine: $73,373

Branded share of claims

21.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 186 $235,025
Eliquis Apixaban Brand 272 $186,351
Farxiga Dapagliflozin Propanediol Brand 131 $92,920
Jardiance Empagliflozin Brand 116 $82,700
Januvia Sitagliptin Phosphate Brand 79 $50,658
Mounjaro Tirzepatide Brand 38 $41,925
Trulicity Dulaglutide Brand 62 $41,357
Myrbetriq Mirabegron Brand 58 $26,131
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 41 $25,183
Xarelto Rivaroxaban Brand 41 $21,821

The 10 drugs with the highest cost, of 199 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 109 billing codes

Paid by Medicare

$265,783

Of which drugs: $22,579

Medicare patients

486

Average age 77

Services billed

10,057

219 women, 267 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 45%
Arthritis 45%
Chronic kidney disease 33%
Ischemic heart disease 31%
Depression 31%
Heart failure 23%
Atrial fibrillation 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 132 132 $10,800
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 39 40 $6,260
Sarscv2 vac 30mcg trs-suc im 91320 Office 27 27 $4,028
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 19 234 $52
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 14 34 $31
Injection, ketorolac tromethamine, per 15 mg J1885 Office 20 60 $28

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $108
$108 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $91
$91 15 —
JARDIANCE
  • Lilly USA, LLC $62
$62 116 —
RYBELSUS
  • Novo Nordisk Inc $59
$59 17 —
Ozempic
  • Novo Nordisk Inc $59
$59 186 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

314 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record